Cambridge-based Sage Therapeutics will reduce its workforce by nearly 96%, laying off 338 employees, as the company prepares for acquisition by Supernus Pharmaceuticals in a deal valued at up to $795 million. The cuts, effective August 22, 2025, signal a watershed for the Boston-area biotech scene and highlight continued turbulence in the sector.

Major Layoffs as Part of Acquisition

Sage Therapeutics, once a rising star celebrated for its neuroscience drug pipeline, announced that 338 out of its 353 full-time employees will be let go as part of the integration process with Maryland-based Supernus Pharmaceuticals. This decision comes just weeks after the public disclosure of the acquisition, with the layoffs documented in state WARN filings on June 27. While such deep cuts are not uncommon in biotech mergers, the scale at Sage reflects broader pressures facing the industry in 2025, with firms increasingly prioritizing portfolio consolidation and cost efficiency.

Deal Structure and Strategic Rationale

The Supernus deal, projected to close in the third quarter of 2025, will see the company pay $594 million upfront for Sage, along with up to $201 million in milestone payments. The acquisition represents Supernus’ largest to date. In a statement, CEO Jack Khattar characterized the acquisition as a transformative step intended to bolster Supernus’ portfolio around central nervous system disorders, accessing Sage’s flagship asset, Zurzuvae, and deepening the company’s R&D pipeline.

Zurzuvae (zuranolone), approved by the US Food and Drug Administration (FDA) in August 2023, became the first oral medication specifically authorized for the treatment of postpartum depression (PPD), a condition affecting approximately 1 in 8 women in the United States according to CDC estimates. The launch of Zurzuvae was heralded as a breakthrough, but commercial uptake has been slower than anticipated, contributing to Sage’s mounting financial headwinds and ultimately making an acquisition more attractive.

Challenges Leading Up to the Sale

Sage’s journey from high-flying biotech to acquisition target was marked by a series of clinical and commercial setbacks in recent years. After going public in 2014, Sage built its reputation on pioneering therapies for central nervous system (CNS) diseases. However, its fortunes shifted following the FDA’s decision in August 2023 to deny approval for Zurzuvae in the much larger indication of major depressive disorder (MDD). The setback not only dashed hopes for blockbuster sales but also led to a 40% reduction of Sage’s workforce last year. In April 2024, further disappointment followed as a once-promising Parkinson’s disease drug candidate failed to achieve efficacy in clinical trials, prompting Sage to discontinue the program entirely. By January 2025, after rejecting a $469 million bid from former partner Biogen on grounds of undervaluation, the company was running short of strategic options—a sentiment echoed by Boston biotech observers watching funding tighten across the sector.

These challenges have mirrored wider trends in the biotech industry in 2024 and 2025, as companies grapple with higher interest rates, cautious capital markets, and a “risk-off” environment from investors that has led to workforce reductions and increased consolidation activity.

Supernus Pharmaceuticals: Expanding CNS Focus

Supernus Pharmaceuticals, with nearly 450 employees and a $1.6 billion market cap prior to the deal, has spent decades building a niche in central nervous system disorders. Its current portfolio includes treatments for epilepsy (Oxtellar XR, Trokendi XR), Parkinson’s disease (Apokyn), attention deficit/hyperactivity disorder (Adhansia XR, Qelbree), migraines (Trokendi XR), and more. Supernus aims to leverage its existing commercial infrastructure to accelerate the uptake of Zurzuvae, particularly through established relationships with neurologists and psychiatrists.

Khattar noted, “The acquisition of Sage and its innovative drug Zurzuvae strengthens our leadership in CNS therapeutics and provides further momentum for growth.”

Zurzuvae: A Unique, Yet Challenging Asset

Zurzuvae’s 2023 approval was historic in women’s mental health, offering the first oral treatment for postpartum depression—a field long underserved by pharmaceutical innovation. Analysts initially estimated a potential U.S. market of over $1 billion annually for PPD drugs. Yet, insurance coverage hurdles, slow provider uptake, and heightened competition have limited realized sales, with Sage reporting only modest early revenues for Zurzuvae through early 2025. Supernus aims to address these shortcomings, leveraging its payer and physician networks for broader access and adoption.

The Future for Sage Employees and Boston Biotech

The layoffs at Sage follow a difficult period for the Boston-area biotech ecosystem, which has experienced waves of job cuts as high funding costs and a more discriminating investor environment force consolidation and reprioritization. According to MassBio, biotech employment in Massachusetts shrank by 3% in 2024—the first Year-over-Year decline in more than a decade. Many outgoing Sage employees are highly skilled scientists and clinical development professionals, and local biotech observers are hopeful that their expertise will find new homes in other ventures or startups that continue to seek breakthroughs in neuroscience and mental health.

Massachusetts remains the leading hub for life sciences innovation, with ongoing investments in lab infrastructure and talent, though the climate continues to be challenging for early-stage companies.

Industry Outlook: More Deals on the Horizon?

Sage’s acquisition is emblematic of a broader trend in the biotech industry, where large pharma companies and established specialty firms are increasingly using M&A to acquire late-stage assets and diversify risk. Other recent deals, such as Eli Lilly’s $1.3 billion purchase of gene-editing specialist Verve Therapeutics, suggest continued momentum for consolidation in 2025.

For Supernus, the focus shifts to maximizing the value from Zurzuvae while integrating select Sage personnel and pipeline assets. As capital markets for biotech remain tight, further waves of consolidation and strategic partnerships are expected, leaving a transformed but hopeful landscape for pharma innovation in the years ahead.